Fred E. Cohen

Dr. Cohen is a former academic clinician with many years of experience advising pharmaceutical and life sciences companies. Dr. Cohen has served as a director for UroGen since May 2017.

Dr. Cohen is a Senior Advisor to TPG Capital, where he served for more than 15 years as a Partner, and founder of TPG Biotechnology, a life science-focused venture capital fund.

Beginning in November 2017, Dr. Cohen has served as a co-founder and senior managing director of Vida Ventures, LLC, a biotechnology venture capital fund.

In addition, for more than two decades throughout his career, Dr. Cohen has been affiliated with the University of California, San Francisco, where he has held various clinical positions, including as a research scientist, an internist for hospitalized patients, a consulting endocrinologist, and the Chief of the Division of Endocrinology and Metabolism.

Dr. Cohen also currently serves on the board of directors of Progyny, CareDx, and Intellia Therapeutics.

Dr. Cohen received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil in Molecular Biophysics from Oxford on a Rhodes Scholarship, and his M.D. from Stanford. He is a member of the National Academy of Medicine and the American Academy of Arts and Sciences.

Dr. Cohen currently serves on the board of directors of several other biotechnology and pharmaceutical companies.